When you are cured, the world cheers; when you are dying, it mourns. But when you are simply maintaining, the world is at a loss
M
ornings begin with a silent inventory, conducted in the dark before the curtains are drawn: can I breathe easily today? The question is stripped of all poetic veneer. When you have stage four lung cancer, breath is no longer a background process; it is a finite currency I must spend with the caution of a miser. It dictates the architecture of my day, the borders of my energy and the very cadence of my speech.
I am not a “survivor” in the triumphalist sense of the word, nor am I imminently dying. I occupy the long middle – a rarely charted territory where the body remains fragile, treatment constant, and life does not so much move forward as stubbornly persist.
This liminal state is a distinctly modern byproduct of a medical revolution. In the UK, barely a decade ago, a stage four lung cancer diagnosis was a grim cliff edge; when the NHS standard was rooted in traditional chemotherapy, long-term survival remained in the single figures. Today, the momentum of clinical progress, driven by the maturing precision of immunotherapy and the success of targeted therapies, has levelled that precipice into a vast, uncharted plateau. While median survival is now measured in years rather than months, we are seeing the emergence of “super-responders” navigating their second decade post-diagnosis. As a psychologist, I view this not just as a medical victory but as a profound existential shift: we have replaced the suddenness of the cliff with the tenuous permanence of the high ridge.
